1
cells and could be potentially synthetically lethal 24, 25 . Taken together, these data provide 1 definitive evidence of mutation co-occurrence at cellular level and provide a landscape of clonal 2 relationship among AML driver mutations (Extended Data Fig. 8 and 9 ). 3 4 Zygosity of AML driver mutations 5
One of the unique aspects of scDNA-seq is its capability of calling mutations in 6 individual cells with zygosity information. In fact, a previous single-cell study reported the 7 cellular diversity in the zygosity of NPM1 and FLT3 mutations in AML 4 . However, the lack of 8 validation method has made the interpretation of zygostiy difficult. In the current cohort, 9 mutations in genes such as FLT3-ITD, GATA2, JAK2, NPM1, RUNX1, and SRSF2 were 10 frequently detected as homozygous (Extended Data Fig. 10 ). Because amplicons covering some 11 of these mutations (GATA2, RUNX1, and SRSF2) had relatively low sequencing depth (Extended 12 Data Fig. 1) , it is possible that some homozygous calls were the result of low sequencing depth 13 and ADO. To validate zygosity called by the scDNA-seq, we performed SNP arrays in selected 14 samples with homozygous mutation calls. In AML-25-001, 97% of the cells had a homozygous 15 RUNX1 p.Q335X mutation determined by scDNA-seq data, and SNP array data detected a copy-16 neutral loss of heterozygosity (CN-LOH) on chromosome 21 involving RUNX1 ( Fig. 2a ). 17
Similarly, in AML-03-001, 66% of the cells had a homozygous FLT3-ITD mutation determined 18 by scDNA-seq data, and the SNP array detected CN-LOH on chromosome 13 involving FLT3 19 ( Fig. 2b) . These results indicate that the observation of homozygosity of the RUNX1 and FLT3-20 ITD mutations in these cases was true and was a result of CN-LOH. In contrast, none of the 21 samples with homozygous SRSF2 (17% of the cells genotyped as homozygous in 22 Fig. 2c) or NPM1 (13% of the cells genotyped as homozygous in AML-13-001, Fig. 2d ) 23 mutations had allelic imbalance involving the mutated loci. These results do not rule out the 1 possibility that the SNP arrays missed the subclonal allelic imbalance. However, the cells that 2 were genotyped as homozygous had significantly lower sequencing depth than did the cells that 3 were genotyped as heterozygous ( Fig. 2c-d and Extended Data Fig. 11 ), suggesting that the 4 homozygous calls in these mutations may have resulted from low sequencing depth and ADO. 5
For cases with validated homozygous calls, the zygosity of the mutations added further 6 resolution to the interpretation of the clonal substructure of the samples (Fig. 2a-b and Extended 7 Data Fig. 11 ). 8 9
Reconstructing mutational histories in AML 10
To reconstruct mutational histories in AML, we used SCITE, a probabilistic model to 11 infer phylogenetic trees from single-cell sequencing data that involves a flexible Markov-chain 12
Monte Carlo (MCMC) algorithm 26 (Supplemental Methods) . Reconstructed phylogenies 13 revealed both linear and branching evolution patterns in AML (Extended Data Fig. 12 ). Patients 14
showing branching evolution had a significantly higher number of mutations, compared with 15 those with linear evolution (median number of mutations 5 [IQR: 4-6] vs. 3 [IQR: 2-4], p < 16 0.001, Fig. 3a ). In cases with linear evolution pattern, ancestral mutations often involved 17 DNMT3A, IDH2, and SRSF2 mutations that have been detected as preleukemic clonal 18 hematopoiesis 27,28 followed by sequential accrual of secondary mutations that frequently 19 involved NPM1, FLT3, RUNX1, NRAS, KRAS, 12) 13, 29 . In some cases with branching pattern, we observed the evolutionary history that is 21 consistent with convergent evolution. For example, in AML-38-001, a putative founding 22 mutation, NPM1 p.L287fs, generated 2 independent branches with IDH1 p.R132H or IDH2 23 p.R140Q mutations. Each of these branches then separated into PTPN11 p.D61H or KRAS 1 p.G12A mutations and FLT3-ITD, NRAS p.G13R, PTPN11 p.A72G, or NRAS p.G12A 2 mutations, respectively. As a result, the sample carried 9 clones, each with a combination of 3 similar, but separately evolved, molecular alterations (NPM1-IDH-RAS/RTK pathway alteration) 4 and the same mutation order (Fig. 3f ). Other cases exhibiting evidence of branching evolution 5 are shown in Fig. 3g -i and Extended Data Fig. 12 . These data with convergent evolution indicate 6 the presence of selective pressure in a bone marrow ecosystem that favors AML clones having 7 certain combination of molecular alterations with a fixed order. 8 9 Clonal remodeling under therapeutic pressure 10
We then analyzed 24 longitudinal samples from 10 patients (8 with baseline and relapse 11 pairs and 2 with multiple refractory timepoints) to study the evolution of clonal architecture in 12 response to therapies ( Fig. 4 and Extended Data Fig. 13 ). We observed clonal selection and 13 adaptation under the therapeutic pressure that were associated with the patients' clinical courses. 14 For instance, AML-09 was a 74-year-old man with previously untreated AML with NPM1 15 p.L287fs, FLT3-ITD, FLT3 p.D835E, FLT3 p.D835Y, and KRAS p.G13D mutations. The patient 16 was treated with azacitidine and sorafenib and experienced morphological complete remission 17 (i.e. leukemic blast less than 5% in marrow with normal recovery of blood counts). However, 5 18 months later, his AML relapsed. scDNA-seq of the baseline-relapse pair revealed that NPM1-19 FLT3 p.D835Y clone, originally a subclone that constituted 1.7% of the diagnostic sample, was 20 selected during the therapy, suggesting that clonal selection is the underlying mechanism of 21 relapse in this case (Fig. 4a ). This clonal selection is consistent with the known in vitro 22 differential sensitivity of various FLT3 mutations to sorafenib; indeed, the FLT3 p.D835Y 23 mutation was shown to be more resistant to sorafenib than were the D835E and ITD mutations 1
. 2
The second case AML-21 is a 56-year-old-woman with newly-diagnosed AML who was 3 treated with induction chemotherapy with clofarabine, idarubicin, and cytarabine followed by 4 4 additional cycles of consolidation therapy. After approximately 7 months of remission, her 5 disease relapsed. While both baseline and relapse samples shared ancestral WT1 p.A382fs -6 NPM1 mutations, the NRAS clone was replaced by the FLT3-ITD-WT1 p.S381fs clone at relapse 7 (the acquired WT1 p.S381fs mutation was in trans, making biallelic WT1 mutations at relapse, 8
Extended Data Fig. 14) . These FLT3-ITD and WT1 p.S381fs mutations were undetectable at 9 baseline. They were likely acquired de novo at relapse or sub-detectable at baseline and were 10 selected during the therapy (Fig. 4b) . 11
Finally, two treatment refractory AML cases showed highly adaptive clonal structure 12 during therapy. Both AML-38 ( Fig. 4c , the same case in Fig. 3f ) and AML-04 ( Fig. 4d ) had 13 AML with multiple branching clones. In both cases, treatment with a FLT3 inhibitor-containing 14 therapy decreased clones with FLT3 mutations, however with a concurrent expansion or 15 selection of other clones and development of new clones. High clonal diversity in both cases 16 seems to have allowed these AMLs to flexibly re-configure their clonal composition during 17 therapy, which likely contributed to the therapeutic resistance ( Fig. 4c-d ). These data from 18 longitudinal cases illustrate the evolution of clonal architecture under the selective pressure of 19 therapy and elucidate the role of clonal selection and adaptation in therapy resistance and 20 relapse. 21
22

Association between clonal diversity and clinical outcomes 23
We then analyzed the clinical implications of clonal diversity in AML that is uncovered 1 by our single-cell sequencing. The median number of cell subclones per patient was 4 (IQR: 3-2 5). Using the median as a cut-off, we divided the patients into lower (<4 subclones) and higher 3 clonal diversity (≥4 subclones) groups. Patients with higher clonal diversity were significantly 4 older compared with those with lower clonal diversity (median age 63 vs. 56 years, p = 0.0283). 5
Patients with higher clonal diversity were more likely to have a secondary or therapy-related 6 disease, relapsed/refractory disease, and tended to harbor chromosomal abnormalities detected 7 by karyotyping, although the differences were statistically not significant. Among the 64 8 previously-untreated cases, those with higher clonal diversity had a trend toward lower CR rate 9 compared with those with lower clonal diversity (CR rate 78% vs. 97%, p = 0.0534, Fig. 5a ). 10
Also, AML patients with higher clonal diversity showed significantly worse overall survival 11 (OS) compared with those with lower clonal diversity (2-year OS 25 vs. 59 months, p = 0.0469; 12 Using a novel high-throughput scDNA-seq platform, we determined the clonal 16 architecture of AML at single-cell resolution and described the clonal relationships among AML 17 driver mutations. Cell-level co-occurrence and mutual exclusivity data obtained from this study 18 provide the rationale for future studies investigating the cooperative mechanism, functional 19 redundancy, and synthetic lethality among oncogenic mutations. Reconstruction of mutational 20 history based on the single-cell data not only revealed inter-tumor diversity in the evolutionary 21 history of AML but also provided evidence for linear and branching evolution patterns in AML 22 with some cases exhibiting convergent evolution. In cases with convergent evolution, we 23 observed clones that evolved separately but with a similar coalescence of molecular alterations, 1 which is similar to the observations in other studies utilizing multi-region/site sequencing or 2 single-cell analysis for different tumors 6,31-34 . These observations indicate for an underlying 3 genetic instability and evolutionary adaptation of AML clones to selective pressure in tissue 4 ecosystem. Cancer therapies, particularly molecularly targeted therapies, provide additional 5 selective pressure to AML clones, which facilitates selection of resistant clones and acquisition 6 of new mutations or clones, leading to recurrence or treatment resistance. 7
This work represents the largest cohort of AML patients yet examined at single-cell 8 resolution, moves a growing body of data 4,6 forward into a deeper understanding of the 9 fundamental clonal architectures of AML. The depth of both patient numbers and cells 10 sequenced allowed a robust analysis of the clonal relationship and phylogeny in this study 11 despite the technical challenges associated with single-cell sequencing, such as but not limited 12 to, ADO, multiplets, coverage inconsistency, and false positives. Moreover, a large sample size 13 allowed the description of inter-tumor diversity in the patterns of clonal evolution, and offered 14 some indication that clonal diversity affects prognosis in AML. Here, we interrogated 19 known 15 leukemia driver genes that have given rise to a remarkable level of clonal complexity in AML. It 16 is noteworthy that this is still an underestimation of the true extent of clonal diversity. Future 17 studies with even more cells, broader coverage of the genome, and integration with single-cell 18 transcriptomic and epigenomic states, that is becoming a reality with the recent technological 19 advancement 35 36 , will further elucidate the clonal diversity and evolutionary trajectories of 20 AML, which may contribute to the development of predictive biomarkers or therapies targeting 21 clonal diversity. 22
METHODS 1
Patients and samples 2
We included in the analysis 91 samples (89 bone marrow mononuclear cells and 2 3 peripheral blood mononuclear cells) from 75 patients with AML and 2 patients with high-risk 4 myelodysplastic syndrome who had at least one somatic mutation covered by the targeted panel 5
for scDNA-seq. In order to avoid allelic imbalance, samples with a normal karyotype were 6 prioritized for analysis. For samples that exhibited cytogenetic abnormalities, we confirmed that 7 the chromosomal position of the examined somatic mutations did not overlap with the regions 8 with a structural variation. Of the 77 patients, 67 patients were analyzed for the single-timepoint 9 sample including pre-treatment (N=59), relapse (N=5), and random timepoint with refractory 10 disease (N=3). For the remaining 10 patients, we analyzed the longitudinal samples obtained at 11 pre-treatment and relapse (N=6), pre-treatment, during treatment, and relapse (N=2), and 3 12 random refractory timepoints (N=2). All the patients provided written informed consent for 13 sample banking and analysis. The study was approved by the MD Anderson institutional review 14 board and was in accordance with the Declaration of Helsinki. 15
Variant detection by single-cell DNA sequencing 16
We used a novel microfluidic approach with molecular barcode technology to amplify the 17 DNA from individual cells as previously described 10 . Briefly, cryopreserved bone marrow 18 mononuclear cells were thawed, and cells were quantified using a Countess Automated Cell 19
Counter (Thermo Fisher). The cells were resuspended in cell buffer and diluted to a 20 concentration of 2,000,000 to 4,000,000 cells/mL. Next, 100 µL of cell suspension was loaded 21 onto a microfluidics cartridge and cells were encapsulated on the Tapestri instrument followed 22 by the cell lysis and protease digestion on a thermal cycler within the individual droplet. The cell 23 lysate was then barcoded such that each cell had a unique label. The barcoded samples were then 1 thermocycled using 50 primer pairs specific to a panel of 19 mutated genes covering known 2 AML-related hotspot loci and 10 commonly heterozygous SNP loci for ADO determination 3
( Supplementary Table 4 ). 4
The pooled library was sequenced on an Illumina MiSeq system with 150-or 250-base 5 pair (bp) paired-end multiplexed runs. Detailed methods are provided in the Supplemental 6
Methods. Briefly, fastq files generated by the MiSeq instrument were processed using the 7 Tapestri Analysis Pipeline for adapter trimming, sequence alignment, barcode correction, cell 8 finding, and variant calling. Loom files that were generated by the pipeline via GATK-based 9 haplotype calling were then processed using in-house filtering criteria. We included cells for 10 downstream analysis that met the following criteria for genotyping: total read count (depth, DP) 11
100×). Cells that did not satisfy these criteria were considered to have missing genotypes. 13
The ADO rate was calculated on the basis of common SNP information using 10 14 amplicons designed to cover 10 highly polymorphic loci in the Tapestri Single-Cell DNA AML 15
Panel. 16
Mutation detection by bulk sequencing 17
As an orthogonal validation, all samples were concurrently sequenced by conventional 18 bulk next-generation sequencing (NGS) using target-capture deep sequencing (N = 66, median 19 coverage: 432×, IQR: 283×-610×) or whole-exome sequencing (N = 11, median coverage: 146×, 20 IQR: 86×-158×). Target-capture NGS was performed using a SureSelect (Agilent Technologies) 21 custom panel of 295 genes that are recurrently mutated in hematological malignancies 22
( Supplementary Table 5 ). Detailed methods were previously described 11 . Briefly, genomic DNA 23 was extracted using an Autopure extractor (QIAGEN/Gentra) and was fragmented and bait-1 captured in solution according to the manufacturer's protocols. Captured DNA libraries were 2 then sequenced using a HiSeq 2000 sequencer (Illumina) with 76-bp paired-end reads. Whole-3 exome sequencing was performed using SureSelect V4 exome probes (Agilent Technologies) 4 and a HiSeq 2000 sequencer (Illumina) with 76-bp paired-end reads. Modified Mutect and Pindel 5 algorithms were used for mutation calling as described previously 11 . 6
Comparison of genotype results from scDNA-seq and bulk sequencing 7
To determine how the models of clonal architecture obtained using the 2 sequencing 8 methods differed, we compared the VAF from bulk sequencing (bulk VAF) and the VAF from 9 single-cell genotype data (scDNA-seq VAF). scDNA-seq VAF was calculated as follows based 10 on the sequencing reads from the pooled single cells: (number of the single-cell sequencing reads 11
with alternate allele) / (number of total single-cell sequencing reads). 12
Inference of mutational histories 13
We used the SCITE (Single Cell Inference of Tumor Evolution) software to infer 14 phylogenetic trees of the driver mutations from scDNA-seq data as previously described 26 . 15 SCITE is an MCMC-based Bayesian inference scheme that can be used to find a mutation tree (a 16 partial temporal order of mutations) that best fits the observed single-cell genotypes. The 17 concentration on the mutation tree (as opposed to a cell lineage tree) makes the use of SCITE 18 very efficient for use with our data that is characterized by few mutational events and many cells. 19 SCITE operates with 2 parameters, one for the false positive rate (FPR) and one for the 20 false negative rate, which can be either set to predefined values or inferred in the MCMC model 21 along with the tree structure. We used a global estimate of the sequencing error rate as the FPR 22 (1%) and dataset-specific estimates of the dropout rate (ADO provided by the platform) as the 23 false negative rate (FNR). In cases where no dropout rate was estimated, we let SCITE learn the 1 value from the data by giving it the average value of the estimates across all patients as a prior 2 estimate. We ran SCITE separately for each patient, providing the table of mutation calls as the 3 input (encoding 0 for wild-type, 1 for mutation, and 3 for missing data point). To obtain a robust 4 model, we ran SCITE with 4 different combinations of parameters: 1) use all cells including 5 missing genotype information with 1% FPR and SCITE inferred FNR, 2) use all cells including 6 missing genotype information with 1% FPR and platform provided FNR, 3) use only cells with 7 full genotype information with 1% FPR and SCITE inferred FNR, and 4) use only cells with full 8 genotype information with 1% FPR and platform provided FNR. When provided with an 9
incomplete genotype for a cell, SCITE is still able to use the partial genotyping information in 10 the tree inference and assigns cells into subclones based on the available information. 11
The inference procedure underlying SCITE is fully Bayesian, which allowed us to 12 quantify uncertainty in the inferred clonal architectures by sampling trees from the model's 13 posterior distribution. We summarized the sampled trees by reporting 95% credible intervals for 14 the inferred subclones. 15
The tree structure (branching vs. linear) were mostly consistent among the 4 models (47 16 of 76 [62%] cases showing consistent tree structure, Extended data. Fig. 12 ). Phylogeny figures 17 that are shown in Fig. 3 are based on model 2 (all cells, 1% FPR, and platform provided FNR). 18
For longitudinal samples, we combined the scDNA-seq data from all time points from the same 19 patient and ran SCITE for the pooled data, and reconstructed the tumor phylogeny. To obtain 20 time point-specific estimates of subclone sizes, we performed the cell to subclone assignment in 21 the posterior sampling separately for each time point. As in some cases not all mutations were 22 observed at all time points, we adjusted the assignment probabilities such that a cell cannot be 23 placed below any mutation unobserved at the cell's sampling time. This leads to subclones with a 1 temporary prevalence of 0%. This does not necessarily mean that the subclone was non-2 existent/extinct at that time, but simply reflects the lack of evidence for its existence based on the 3 cells sampled at the respective time point. The number of subclones was defined as the number 4 of distinct cellular populations carrying at least one mutations based on model 2. 5
SNP array 6
Genomic DNA from 28 samples in which scDNA-seq data showed at least 5% of 7 homozygously mutated clones were analyzed by Illumina Omni2.5-8 SNP array. The raw data 8 retrieved from an Illumina Omni2.5-8 SNP array was processed using GenomeStudio 2.0. The 9 raw log R ratio and B allele frequency were used for ASCAT (allele-10 specific copy number analysis of tumors) algorithm 37 to identify copy-number alterations. 11
Droplet digital PCR 12
We performed droplet digital PCR (ddPCR) using QX200 TM was used to assess the relationships between two continuous variables that did not follow a 7 normal distribution. To evaluate cell-level co-occurrence and mutual exclusivity, a contingency 8 table was constructed to compute the log2-transformed odds ratios. Fisher's exact test was used 9
to evaluate the statistical significance of associations. The Benjamini-Hochberg method was used 10 to adjust for multiple testing 38 . In order to assess the prognostic relevance of clonal 11 heterogeneity, we collected survival information for previously-untreated 64 AML patients. 12
Overall survival was calculated from the date of pretreatment sample collection to the date of 13 death from any cause, and censored on the date of last follow-up if alive. Those who underwent 14 stem cell transplantation was censored on the date of transplantation. Kaplan-Meier plots were 15 used to visualize survival distributions. Differences in survival between groups were analyzed 16 using log-rank tests. We considered P value of less than 0.05 to be statistically significant. R 17 (ver. 3.4.3) and EZR 39 software packages were used for statistical analysis. 18
Code availability 19
Publicly available codes were used with a citation for data analysis. In-house codes that were 20 used for single-cell sequencing data variant calling are available from the corresponding author 21 on reasonable request. 22
Data availability 23
Deidentified clinical and genetic data is available in supplementary information. Somatic mutations in 556,951 cells from 77 AML patients detected by single-cell DNA 5 sequencing. Each column represents a cell, and cells from the same case are clustered together 6 within the areas surrounded by the grey lines. Note that some cases are difficult to be segregated 7 in print. Cells that were genotyped as being mutated or wild type for the indicated gene are 8 colored in blue and white, respectively. Cells with missing genotypes are colored in grey. When 9 one sample has multiple different mutations in the same gene, they were annotated differently 10 (e.g., NRAS_a, NRAS_b). A total of 57,953 cells that were genotyped as wild type for all the 11 
Fig. 2. Homozygous variants involving copy-neutral loss of heterozygosity. a-d, 20
Representative cases with highly homozygous variants analyzed by SNP array. The bar graphs 21 on the left show the distribution of zygosity for each indicated variant. Cells that were genotyped 22 as having heterozygous and homozygous mutations are shown in blue and red, respectively. The 23 numbers on the bars represent the number of cells with each genotype. The figures in the middle 1 show the distribution of the allele counts for the two alleles (green or red). The allele count is 2 shown on the vertical axes, and the chromosomes are shown on the horizontal axes. The 3 chromosomes on which the highly homozygous variants were located are highlighted with blue 4 rectangles. Distributions of depth are shown in the figures on the right based on the genotype 5 calling. Heat maps incorporating the zygosity information are also shown for cases with 6 
